clinical trial · NCT06554639
A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
Merck Sharp & Dohme LLC·phase1·completed·n = 12
Prostatic NeoplasmsMK-5684PrednisoneFludrocortisone acetateDiltiazem hydrocholoride
brief summary
Researchers have designed a study medicine called MK-5684 as a new way to treat prostate cancer. The purpose of this study is to learn what happens to MK-5684 in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to MK-5684 in the body when it is given with and without another medicine called diltiazem.
started
Jul 11, 2024
primary completion
Aug 5, 2024
completion
Aug 29, 2024
last updated
Oct 15, 2024
official title
A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effects of Multiple Doses of Diltiazem on the Single-Dose Pharmacokinetics of MK-5684 in Healthy Adult Male Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol